MYOKARDIA

MyoKardia is a pioneering biopharmaceutical company discovering and developing targeted treatments for patients diagnosed with serious and underserved cardiovascular diseases. Our pipeline includes therapies for hypertrophic cardiomyopathy, genetic forms of dilated cardiomyopathy, and heart failure with preserved ejection fraction... At AHA Scientific Sessions 2020, phase 3 data in hypertrophic cardiomyopathy (HCM) will be presented. MyoKardia is a pioneering biopharmaceutical company that is leading the way in targeted therapies for underserved cardiovascular diseases.

Also known as: MyoKardia Congresses